23.05.2016 • NewsElaine BurridgeGenentechchemotherapy

Genentech’s Bladder Cancer Drug Wins US Approval

Genentech has won an accelerated approval from the US Food and Drug Administration (FDA) for bladder cancer treatment Tecentriq. The immunotherapy has been cleared to treat patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

The drug’s accelerated clearance was based on the tumour response rate and duration of response seen in a Phase II trial. However, continued approval may need to be verified in confirmatory trials.

Genentech is also evaluating Tecentriq in a confirmatory Phase III study. This trial compares the drug to chemotherapy in people whose bladder cancer has progressed on at least one prior platinum-containing regime.

Bladder cancer is the fifth most commonly diagnosed cancer in the US and mUC accounts for 90% of all cases. Only 39% of people in advanced stages of the disease survive five or more years.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.